---
title: >-
  Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using
  Non-Invasive Tests from TARGET-NASH Study.
description: >-
  Explore this publication on real-world evidence: Determination of Optimal
  Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from…
date: '2021-01-01'
category: Publications
tags:
  - Poster Presentation
  - R&D
  - Care
  - Hepatology
  - MASH/MASLD
  - Pharma Partner
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/poster-presentation/determination-of-optimal-thresholds-for-significant/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: determination-of-optimal-thresholds-for-significant
id: 6qmyhHPeeWMou50LTqeZ5U
contentType: article
---

## Challenge

Standard FIB-4 and APRI thresholds for advanced fibrosis were derived from clinical trial populations, not real-world NAFLD cohorts, leaving uncertainty about whether the same cutoffs performed optimally in a heterogeneous real-world population with the full spectrum of disease severity.

## Solution

The TARGET-NASH cohort was used to derive optimal NIT thresholds for significant fibrosis (≥F2) using AUROC analysis against locally interpreted liver biopsies, generating high-specificity and high-sensitivity cutoffs for FIB-4 and APRI in a real-world population.

## Impact

Providing real-world-derived optimal NIT thresholds for significant fibrosis in NAFLD enables more accurate patient identification for clinical trials targeting early-stage disease and supports the development of NIT-based enrollment enrichment strategies.

### [Andrea R. Mospan](/people/andrea-mospan/)

![Andrea R. Mospan, PhD, RAC — Profile Photo](https://images.ctfassets.net/h4s3ip99qawo/4w6bkwPHPqrXKYs4tHZPkK/1d21763b54ecc3466764986693b7072f/andrea-mospan.jpg)